THE LONG-TERM RETENTION OF PLATINUM IN HUMAN TISSUES FOLLOWING THE ADMINISTRATION OF CISPLATIN OR CARBOPLATIN FOR CANCER-CHEMOTHERAPY

被引:71
作者
TOTHILL, P
KLYS, HS
MATHESON, LM
MCKAY, K
SMYTH, JF
机构
[1] WESTERN GEN HOSP,DEPT PATHOL,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND
[2] SCOTTISH UNIV RES & REACTOR CTR,E KILBRIDE G75 0QU,LANARK,SCOTLAND
关键词
D O I
10.1016/0959-8049(92)90519-8
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Mass spectrometry has been used to study the distribution and retention of platinum in the tissues of patients following the administration of cisplatin or carboplatin. Blood platinum was measured up to 2 years and renal excretion up to 5 years after treatment. Platinum concentrations in plasma and red cells fell according to a power function, approximately as the inverse square of the time after administration. The concentration in the urine fell more slowly. Necropsy samples were used to examine the distribution of platinum in various human organs up to 17 months after treatment. The highest concentrations were found in the liver, which retained approximately 2% of the dose. Although the results were scattered between patients, there was little loss of platinum after about 1 month. The prolonged retention of platinum may be relevant to long-term toxicity.
引用
收藏
页码:1358 / 1361
页数:4
相关论文
共 21 条
[1]  
CASPER ES, 1979, CANCER TREAT REP, V63, P2023
[2]  
DAUGAARD G, 1988, CANCER CHEMOTH PHARM, V21, P163
[3]   CHEMOTHERAPEUTIC AGENT CISPLATIN MONITORING IN BIOLOGICAL-FLUIDS BY MEANS OF INDUCTIVELY-COUPLED PLASMA EMISSION-SPECTROMETRY (ICP-AES) [J].
DOMINICI, C ;
ALIMONTI, A ;
CAROLI, S ;
PETRUCCI, F ;
CASTELLO, MA .
CLINICA CHIMICA ACTA, 1986, 158 (03) :207-215
[4]   PROLIFERATIVE LESIONS IN THE LIVERS OF MICE TREATED 18 MONTHS PREVIOUSLY WITH CISPLATIN [J].
EWEN, C ;
MOORE, JV ;
HARRIS, M .
BRITISH JOURNAL OF CANCER, 1987, 55 (01) :109-110
[5]   PHARMACOKINETICS OF INTRAARTERIAL AND INTRAVENOUS CISPLATIN IN HEAD AND NECK-CANCER PATIENTS [J].
GOUYETTE, A ;
APCHIN, A ;
FOKA, M ;
RICHARD, JM .
EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1986, 22 (03) :257-263
[6]   PHARMACOKINETICS AND PROTEIN-BINDING OF CIS-DICHLORODIAMMINE PLATINUM (II) ADMINISTERED AS A ONE-HOUR OR AS A 20-HOUR INFUSION [J].
GULLO, JJ ;
LITTERST, CL ;
MAGUIRE, PJ ;
SIKIC, BI ;
HOTH, DF ;
WOOLLEY, PV .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1980, 5 (01) :21-26
[7]  
HILL JM, 1975, CANCER CHEMOTH REP 1, V59, P647
[8]   DETERMINATION OF CIS-DIAMMINEDICHLOROPLATINUM(II) IN PLASMA-PROTEINS AND HEMOGLOBIN OF CANCER-PATIENTS [J].
MUSTONEN, R ;
HIETANEN, P ;
LEPPALA, S ;
TAKALA, M ;
HEMMINKI, K .
ARCHIVES OF TOXICOLOGY, 1989, 63 (05) :361-366
[9]   HIGH-DOSE CISPLATIN IN HYPERTONIC SALINE [J].
OZOLS, RF ;
CORDEN, BJ ;
JACOB, J ;
WESLEY, MN ;
OSTCHEGA, Y ;
YOUNG, RC .
ANNALS OF INTERNAL MEDICINE, 1984, 100 (01) :19-24
[10]   CISPLATIN (CIS-DIAMMINEDICHLOROPLATINUM-II) [J].
PRESTAYKO, AW ;
DAOUST, JC ;
ISSELL, BF ;
CROOKE, ST .
CANCER TREATMENT REVIEWS, 1979, 6 (01) :17-39